System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Markus Magerl is an expert in Immunology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Markus Magerl in the top 1% of experts worldwide for Angioedema, Immunologic Deficiency Syndromes and Hypersensitivity. Markus Magerl has authored 297 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 8 of them ongoing. SLR score: 1,320 (community average: 125). How the SLR is computed.

LeadR Profile

Markus Magerl Charité - University Medicine Berlin Germany
1 320 ScienceLeadR Reputation 1320

Unlock

Register Login
Network Map

Immunology

Subspecialties: Dermatology - Cardiology - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1998 - 2026
Source: PubMed

Charité - University Medicine Berlin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 297

Citations

Citations: 12 632 1st author: 40 Last author: 48 Unique author: 2

Main journals

Allergy 40
J Allergy Clin Immunol 35
Ann Allergy Asthma Immunol 16
J Allergy Clin Immunol Pract 16
J Dtsch Dermatol Ges 15

Best Journals

N Engl J Med 4
Lancet 3
JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.
PMID 42894560 — disease management, quality of life, safety, pharmaceutical preparations, angioedemas, hereditary, therapeutics, angioedema		World Allergy Organ J20260
Adverse health outcomes and patient and physician perspectives of attenuated androgen use in hereditary angioedema.
PMID 42892863 — androgens, angioedemas, hereditary, physicians, therapeutics, angioedema		World Allergy Organ J20260
Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.
PMID 42852816 — quality of life, biomedical research, probability, angioedemas, hereditary, antibodies, monoclonal, therapeutics, angioedema		Clin Transl Sci20260
Patient Experience with Treatment of HAE Attacks: Results from a Real-World Survey of Physicians and Their Patients.
PMID 42804082 — drug therapy, physicians, diagnosis, therapeutics, angioedema		Adv Ther20260
Prevalence and impact of sleep disorders in patients with hereditary angioedema: A multicenter cross-sectional study in Latin America.
PMID 42789123 — cross-sectional studies, sleep, angioedemas, hereditary, prevalence, sex, angioedema		Sleep Breath20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 12
Phase 2 8
N/A 3
Phase 1/Phase 2 2

By status:

Completed 14
Active not recruiting 5
Recruiting 3
Terminated 2
Unknown 1

By type:

Interventional 22
Observational 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 4
multicentricup10 19

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An Open Label Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
2023-509201-77-00 — safety, angioedemas, hereditary, therapeutics, angioedema		Phase 3Active not recruiting2022
Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema
2025-522051-26-00 — safety, angioedemas, hereditary, tablets, capsules, therapeutics, angioedema		Phase 3Recruiting2026
CHAPTER 4 A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents
2024-516248-24-00 — safety, angioedemas, hereditary, tablets, adolescent, therapeutics, angioedema		Phase 3Recruiting2025
Long Term Follow Up of Subjects Treated With NTLA 2002
2023-507956-56-00 — angioedemas, hereditary, angioedema		Phase 1/Phase 2Recruiting2024
A Phase 3 Study to Evaluate NTLA 2002 in Participants With Hereditary Angioedema (HAE)
2024-515741-42-00 — complement c1s, safety, angioedemas, hereditary, complement c1 inhibitor protein, esterases, angioedema		Phase 3Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS